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Abstract
To better understand the contribution of methyl-lysine (Kme) binding proteins to various disease 
states, we recently developed and reported the discovery of 1 (UNC3866), a chemical probe that 
targets two families of Kme binding proteins, CBX and CDY chromodomains, with selectivity for 
CBX4 and -7. The discovery of 1 was enabled in part by the use of molecular dynamics 
simulations performed with CBX7 and its endogenous substrate. Herein, we describe the design, 
synthesis and structure-activity relationship studies that led to the development of 1 and provide 
support for our model of CBX7-ligand recognition by examining the binding kinetics of our 
antagonists with CBX7 as determined by surface-plasmon resonance.
Graphical abstract
Introduction
Controlled regulation of gene expression is essential for the proper development and 
function of multicellular organisms. Cell-type specific gene regulation is achieved by 
expression of specific transcription factors and through a complex language of chemical 
modifications to both DNA and histone proteins that are interpreted through the binding of 
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various proteins and protein complexes.1 These ‘reader’ complexes then modulate the 
transcriptional outcome by controlling the accessibility of the underlying gene to 
transcription factors.2, 3
One key chemical modification that regulates gene expression is the posttranslational 
methylation of histone lysine residues.2 The lysine ε-nitrogen can be mono-, di- or tri-
methylated (Kme1, Kme2 or Kme3, respectively). Methyl-lysine (Kme) reader proteins 
recognize Kme in a manner that is specific to the methylation state of the lysine and often to 
the sequence surrounding the modified lysine.3, 4 Kme readers bind methylated-lysine 
through an aromatic cage that engages the lysine side chain through cation-π and van der 
Waals' interactions. The size and shape of the aromatic cage allows the Kme reader to 
discriminate between different methylation states, while the surrounding protein residues 
dictate sequence selectivity.3 Previous studies have characterized the ability of various Kme1 
and Kme2 reader proteins to accommodate non-natural methyl-lysine analogs in their 
aromatic cages;5-7 however, little is known about the preference of Kme3 reader proteins for 
different Kme mimetics. Initial efforts toward the discovery of Kme3 reader antagonists 
were focused on the development of peptidic inhibitors wherein the key Kme3 residue was 
maintained and potency was achieved through the variation of surrounding residues.8, 9
We recently reported the development of 1 (UNC3866), a peptide-based chemical probe that 
contains an unnatural diethyl-lysine in lieu of Kme3 and selectively targets two families of 
Kme3 reader proteins (Figure 1).10 These two families of proteins belong to the 
chromodomain superfamily of Kme readers that are essential for proper genomic regulation 
in numerous organisms, spanning fungi, plants and animals.11 Compound 1 targets the 
Polycomb (Pc) CBX family of chromodomains4 and the lesser explored CDY family of 
chromodomains.12 In mammals, the Pc family of chromodomains consists of five proteins, 
CBX2, -4, -6, -7 and -8. These proteins compete with each other for incorporation into 
Polycomb Repressive Complex 1 (PRC1) where they regulate numerous cellular processes 
including differentiation, growth and proliferation.13-17
Compound 1 is most potent for the chromodomains of CBX4 and -7 (Kd ∼100 nM). It is 6- 
to 63-fold selective for these chromodomains over the other CBX and CDY 
chromodomains.10 Interestingly, our selectivity studies revealed that 1 does not significantly 
interact (Kd >100 µM) with the HP1 family of chromodomains (CBX1, -3 and -5),10 which 
share a high degree of structural similarity to the Pc family of chromodomains but are not 
associated with PRC1.4 Compound 1 was also highly selective versus >250 other molecular 
targets including chromatin regulatory proteins and a general pharmacology panel. Our 
previous studies characterized the effects of 1 in PC3 cells, an advanced stage metastatic 
prostate cancer model previously shown to have its growth regulated by CBX7.18 Consistent 
with CBX7 genetic manipulation, compound 1 is able to inhibit PC3 cell proliferation by 
inducing a senescent-like state.14, 18 These studies suggest that Pc CBX antagonists may one 
day serve as a novel class of therapeutically useful agents.
Herein we report the structure-activity relationship (SAR) studies leading to the 
development of compound 1. We explored the effects of various modifications (Figure 2a) 
on the potency and selectivity versus three representative members of the Pc CBX 
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chromodomains (CBX4, -7 and -8), with CBX4 and -7 being the most potent targets of 1, 
and CBX8 representing the remaining Pc CBX chromodomains (CBX2, -6, and -8), all of 
which display somewhat weaker affinity for 1.10 Compounds were also tested against one 
member of the CDY family of chromodomains, CDYL2, and a representative of the HP1 
family of chromodomains, CBX5, in order to better understand the molecular determinants 
for selectivity between these three structurally related families of chromodomains. 
Additionally, kinetic studies with CBX7 provided key insights into the induced-fit 
recognition mechanism of these ligands by CBX7.
Results and Discussion
We first developed an AlphaScreen®19 assay for each of the Pc CBX and CDY 
chromodomains using His-tagged recombinant protein and 2 (UNC4195, Figure 2b), a 
biotinylated analog of 1, as the bait ligand.10 It should be noted that our previously reported 
AlphaScreen® studies with compound 1 were performed utilizing a similar assay with a 
biotinylated H3K9me3 bait ligand and CBX7. The improved potency of 2 for our target 
chromodomains over the H3K9me3 peptide allows us to reduce the amount of all reagents 
used in the assay and also reduce the tight binding limit. For CBX5, which does not 
appreciably bind to 2, we again utilized a biotinylated version of the endogenous substrate, 
H3K9me34 (see Supplementary Table 1 for specific assay concentrations).
Compound 1 is based on a peptide fragment from the methyltransferase SETDB1 previously 
found to bind more tightly to Pc CBX chromodomains than H3K27me34. The initial 
SETDB1 sequence identified was a 10-residue peptide containing an A-L-Kme3-S motif. 
Therefore, our initial efforts sought to determine the minimal sequence from this peptide 
necessary for Pc CBX antagonism. Using solution-phase peptide synthesis and an N-
terminal benzoyl cap to aid in purification (Supplementary Information, Synthetic Schemes 
1 and 2), we generated a series of peptides based on the ALKme3S motif and found that, 
minimally, a 5 residue peptide (compound 5) is required for antagonism of the CBX 
chromodomains in our panel (Table 1, compounds 3-7). Compound 5 displayed modest 
affinity for CBX4 and -7, weak affinity for CBX8 and CBX5, and submicromolar potency 
for CDYL2. In contrast to the Pc CBX chromodomains, the chromodomain of CDYL2 
maintains weak affinity for the shorter peptides, compounds 3, 4 and 7. Extending the 
peptide length to six residues resulted in compound 6 which displays somewhat reduced 
affinity for each panel member relative to 5, suggesting that there are subtle differences in 
the way these different chromodomains recognize the N-terminus of these molecules. 
Peptide 7 binding affinities were consistent with previous observations that binding of CBX 
chromodomains requires the presence of a serine C-terminal to the methyl-lysine.4, 8
Concomitantly with our studies to investigate the minimal length requirements for 
chromodomain engagement, we had observed robust binding of compound 6 with CBX7 in 
isothermal titration calorimetry (ITC) studies (Kd = 10.3 ± 0.9 µM, Supplementary Figure 
1). Therefore, we sought to use 6 as a scaffold for further SAR exploration in parallel. Nα-
methylation has previously been shown to improve the membrane permeability of peptides20 
so we explored the effect of methylating select backbone amides of 6 on chromodomain 
binding (peptides 8-10). Methylation of the alanine amide nitrogen (8) resulted in loss of 
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binding to all chromodomains tested. Methylation of the phenylalanine amide nitrogen (9) 
selectively bound to CDYL2 while methylation of the glycine amide in compound 10 had 
little effect on binding to any of our panel members when compared to the corresponding 
unmethylated analog (6). These results combined with prior structural studies4, 21 suggest 
that the alanine N-H of these peptides makes a critical hydrogen bond that is necessary for 
binding to chromodomains. The amide N-H of the Phe residue of these and related peptides 
does not appear to be positioned to form any hydrogen bonds when bound to Pc 
chromodomains,10, 21 suggesting that this modification may instead introduce a steric clash. 
Finally, when combined with prior structural studies,4, 10, 21 these results indicate that the 
benzamide cap of both 6 and 10 is solvent-exposed when bound to CBX4, -7 or CDYL2 and 
the Gly amide is likely not making any significant protein contacts.
In parallel with our studies in Table 1, we focused on finding a suitable replacement for the 
Kme3 of 6 in an effort to increase passive membrane permeability and enhance stability 
toward demethylase enzymes22 (Table 2). Consistent with previous studies, the non-
methylated lysine analog of 6, compound 11, displayed no antagonism of any of the 
chromodomains in the panel.4 We performed a series of reductive aminations on 11 
(Supplementary Information, Synthetic Scheme 3) to explore the effect of replacing the 
quaternary amine with bulky secondary amines (compounds 12-16) and in general, found 
that the CBX chromodomains have limited affinity for these secondary amines, while the 
CDYL2 chromodomain is able to bind these ligands with modest affinity. For example, 
simple isopropylation of the lysine (12) showed no affinity for CBX chromodomains but 
single-digit micromolar affinity for CDYL2. Incorporation of a cyclopentyl or cyclohexyl 
(compounds 13 and 14) did not recover CBX activity. Interestingly, fusion of the 5- and 6-
membered rings in norbornyl-lysine (15) showed weak antagonism of CBX7 and equipotent 
antagonism of CDYL2 when compared to cyclopentyl alone (13). Adamantyl substitution 
(16) resulted in no measurable CBX7 activity and CDYL2 activity comparable to the 
cyclohexyl compound (14), indicating that increasing the size of the fused ring system 
beyond norbornyl (15) is not beneficial to chromodomain binding. Taken together, this data 
suggests that CDYL2 is more accommodating to various secondary amine Kme3 
replacements than the CBX chromodomains.
We next focused on the effects of tertiary substitutions at the ε-nitrogen of the lysine 
residue. Unsurprisingly,4, 12 we found that dimethylation (17) reduced the activity for both 
CBX7 and CDYL2 about 3-fold relative to the analogous Kme3 compound (6). However, 
incorporation of a slightly larger diethyl-lysine as in compound 18 resulted in similar 
affinities for all chromodomains as compound 6, albeit with slighted improved affinity for 
CBX8. Encouragingly, this supported the notion that a quaternary amine was not likely to be 
required for potent CBX chromodomain binding. To generate cyclic tertiary amines as in 
compounds 19-21, we reacted 11 with a series of dibromoalkanes (Supplementary 
Information, Synthetic Scheme 3). Cyclization of the diethyl-lysine to generate the 
pyrrolidinyl derivative, 19, resulted in a reduction in potency across the panel, while 
increasing the ring size to a piperidinyl group (20) or a 7-membered azepane (21) also did 
not appear to be beneficial. Incorporation of a bulkier dicyclobutyl-lysine (22) also did not 
result in any significant enhancements in potency.
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We were intrigued by the ability of the norbornyl functionality to weakly interact with 
CBX7 and more potently with CDYL2. It is possible that binding of this functionality to the 
aromatic cage could sterically hinder any cation-π interactions between the cage residues 
and the ε-nitrogen, relying less on the presence of a basic nitrogen for binding. We had 
simultaneously prepared an acetylated version of 15 (compound 23) and although potency 
was reduced approximately 7-fold for CDYL2, the presence of a basic nitrogen does not 
appear to be an absolute requirement for CDYL2 binding. We further interrogated the nature 
of the cation-π interaction at this position by synthesizing the more strongly basic 
tetramethylguanidine derivative by reacting 11 with TBTU in the absence of a carboxylic 
acid to give compound 24, and additionally prepared dibasic compounds 25 and 26 via 
reductive amination (Supplementary Information, Synthetic Scheme 3). All three of these 
compounds showed no activity for the CBX chromodomains and weakened affinity for 
CDYL2. Taken together, the SAR data resulting from modification of the lysine indicates 
that the presence of a quaternary amine is not required for engagement of our 
chromodomain panel; however, only the diethyl-lysine containing compound (18) 
demonstrates a binding profile comparable to that of 6. Substantially improving potency for 
Pc CBX chromodomains through modification of the lysine amine presents a significant 
challenge, but may be a more viable strategy for CDY chromodomain ligand optimization.
Our previously described in silico studies10 on the interaction of CBX7 and an H3K9me3 
peptide provided insight into the mechanism of induced-fit recognition of Kme3 peptides by 
CBX7. These studies suggested that the chromodomain of CBX7 first recognizes the N-
terminal cap residue at the (-4) position from the methyl-lysine, allowing the peptide to 
engage the chromodomain and leading CBX7 to close around the histone and engage the 
Kme3 with its newly formed aromatic cage.10 This induced-fit binding mechanism supports 
peptidomimetics as a likely choice for CBX7 inhibitors and the absence of a preformed 
aromatic cage makes the discovery of traditional small molecule inhibitors a significant 
challenge. Previous studies from the Zhou lab have reported weak, non-peptidic small 
molecule CBX7 ligands; however, SAR studies around these molecules struggled to produce 
significant improvements in potency.21, 23
Our in silico studies led us to hypothesize that the potency of our peptidic antagonists could 
be improved through modification of the N-terminus. Diethyl-lysine was chosen from our 
studies in Table 2 as an optimal Kme3 replacement and hence was incorporated in future 
antagonists while we varied the N-terminus (Table 3, compounds 1 and 27-41; 
Supplementary Information, Synthetic Schemes 1 and 4). Our studies in Table 1 indicated 
that the glycine residue of 6 was dispensable, which led us to prepare compound 27, which 
is the diethyl-lysine analog of compound 5. This compound overall showed similar or 
improved activities toward each of the chromodomains bound by 5, further confirming that 
diethyl-lysine is a suitable Kme3 replacement in the context of this shorter peptide. 
Interestingly, 27 demonstrates measurable affinity for CBX5 in contrast to compound 18, 
providing initial evidence that the aromatic cage of CBX5 can also accommodate non-
natural lysine analogs.
We next began exploring substituents on the N-terminal aromatic ring of 27 by placing a 
methyl substituent at the ortho-, meta- and para-positions. Methylation at the ortho-position 
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(28) of the ring dramatically reduced potency for all chromodomains except for CDYL2, 
causing a 20-fold decrease in binding for CBX7 relative to compound 27. Affinity for all 
chromodomains except CBX5 is recovered to levels comparable to 27 when the methyl 
group is shifted to the meta-position (29). Installation of para-Me (30) results in further 
improvements in binding to CBX7 and CBX4, with submicromolar affinities in each case. 
Interestingly, CBX8 did not display the same preference as CBX4 and -7 for 30 over 29, 
while methylation had little to no effect on CDYL2 binding.
Having determined that, in general, alkylation is preferred at the para-position by Pc 
chromodomains, we next explored the effect of increasing steric bulk at this position 
(compounds 31-32 and 1). Overall, increasing lipophilicity had opposing effects on the 
affinity for Polycomb vs HP1 chromodomains. Introduction of a para-ethyl or para-isopropyl 
substituent as in compounds 31 and 32, respectively, increased the affinity ∼2-5 fold for 
CBX4, -7, and -8, as well as CDYL2, relative to 30, while the affinity for CBX5 was largely 
unchanged or slightly weakened. t-Butyl substitution (1) further improved potency for 
CBX4 and -7 while having no significant effect on the affinity for CBX8 and causing a loss 
of detectable CBX5 affinity. Taken together, these data indicate that potency and selectivity 
can be tuned by systematically adjusting both the position of alkylation and degree of 
lipophilicity on the benzoyl cap at the N-terminus. These studies enabled us to dramatically 
improve the potency of our compounds for CBX4 and - 7, leading to compounds with IC50 
values of less than 100 nM. These results also provided strong support for our molecular 
dynamics studies, which suggested that initial recognition of histones occurs through 
hydrophobic contacts formed between CBX7 and the histone side chain at this position.10
We also evaluated the effect of incorporating electron-withdrawing groups at the para-
position of the N-terminal phenyl cap with compounds 33 and 34. A methyl ester at the 
para-position (33) resulted in an approximately 15-fold loss in potency for both CBX4 and 
-7 relative to compound 1, but only an approximately 3-fold loss in potency for CBX8, 
further suggesting that CBX4 and -7 depend more strongly on the presence of bulky alkyl 
substituents at this position. The strongly electron-withdrawing trifluoromethyl substituent 
of 34 also weakened binding to the Pc chromodomains, although to a lesser extent than 
compound 33. CDYL2 affinity is largely unaffected by replacement of para-alkyl 
substituents with electron-withdrawing groups, consistent with the generally less stringent 
binding preferences of CDYL2. Inclusion of an electron-donating group (35) also did not 
further improve binding to Pc CBX chromodomains, indicating that alkyl substituents at this 
position are preferred. In contrast, these results suggest that CBX5 may prefer less sterically 
demanding functional groups at the N-terminus.
We next investigated the importance of the spacing between the N-terminal hydrophobic 
group and the rest of the peptide. As can be seen with compound 36, addition of a single 
methylene group relative to compound 1 resulted in an approximately 100-fold loss of 
potency for CBX4 and -7 and almost a 20-fold loss for CBX8, while CDYL2 was largely 
unable to distinguish between the t-butyl phenyl and t-butyl benzyl moieties. Additionally, 
larger bicyclic aromatic capping groups with a methylene spacer (37 and 38) were also less 
well tolerated by CBX4, -7 and -8. Consistent with prior results, the increased steric demand 
of these functionalities was detrimental to CBX5 activity.
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Our studies in Table 2 indicated that the tolerance of Pc CBX chromodomains to unnatural 
Kme analogs is fairly limited, yet we were interested in exploring a small number of lysine 
modifications, as well as the native Kme3 residue, in the context of our more potent peptide 
scaffold. We generated the Kme3 analog of 1, compound 39, and two asymmetric tertiary 
amine derivatives, compounds 40 and 41. The isopropyl group of 40 and 41 was 
hypothesized to make additional contacts with the aromatic cage of the Pc CBX proteins and 
to more completely fill the cage based on the crystal structures of 1 bound to these 
chromodomains (Figure 3a). Mirroring prior results, the Kme3 containing compound (39) 
was about equipotent to 1, while the bulkier lysine mimetics of compounds 40 and 41 also 
did not appear to pick up any additional interactions to further improve potency.
Previous studies from the Hof group found that the residue at the (-2) position from the 
modified lysine can have profound effects on the selectivity and potency of peptide 
antagonists for Pc CBX chromodomains.9 We explored this in the context of our antagonists 
by testing the effect of increasing the size of the alkyl side chain at this position (Table 4, 
compounds 42 and 43; Supplementary Information, Synthetic Scheme 4). We found that 
replacing the methyl side chain of alanine with an ethyl or isopropyl group reduced affinity 
for CBX4, -7, and CDYL2 while slightly increasing the affinity for CBX8. This was not 
surprising as previously solved co-crystal structures with 1 revealed that the pocket occupied 
by this alanine side chain is larger in CBX8 than in CBX4 and -7 owing to substitution of 
Val13 in CBX4/7 with Ala13 in CBX8 (Figure 3b).10 The increased potency and modest 
selectivity of 43 for CBX8 may make it a useful starting point for the development of more 
potent and selective CBX8 compounds.
Modifications to the C-terminus of compound 1 (compounds 44-46; Supplementary 
Information, Synthetic Schemes 4 and 5), were reasonably well tolerated. While the methyl 
ester of 1 is the preferred functionality at this position, replacement with the corresponding 
acid (44) or dimethyl amide (45), or removal of the C-terminal carbonyl entirely (46), 
resulted in a mere 2- to 4-fold reduction in potency for Pc CBX chromodomains. 
Interestingly, compound 44 resulted in a slightly larger reduction in potency for CDYL2 (5-
fold), suggesting that additional exploration of the C-terminus of these molecules may be 
useful for further tuning selectivity.
The observed tolerance to modifications at the C-terminus previously led us to generate a 
biotinylated analog of 1 (compound 2). This tool compound showed minimal loss in potency 
for CBX7, and importantly was used to evaluate the selectivity of compound 1 more broadly 
and served as a key chemiprecipitation reagent to demonstrate cellular target engagement.10 
The co-crystal structures of the Pc CBX proteins with compound 1 revealed that the 
phenylalanine of 1 is largely solvent exposed (Figure 3c); therefore, we hypothesized that 
this was an additional position we could use for tagging to access additional tool 
compounds. An amine functional group was installed on the phenylalanine side chain, and 
as expected from the crystallographic information, compound 47 displayed similar affinities 
to 1 for each of the chromodomains in our panel. Further, because the boc group of 48 does 
not interfere with binding, we reasoned that this would be a suitable location to place larger 
chemical moieties. To this end, we generated a biotinylated derivative of 47 (biotin-47; 
Supplementary Information, Synthetic Scheme 6) via modification of the free amine. 
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Compound 2 was previously shown to selectively chemiprecipitate CBX4, -7 and -8, but not 
CBX2 or -6 from PC3 cell lysates, despite having demonstrated affinity for these proteins.10 
Similarly, we found that biotin-47 was unable to pulldown CBX2 and -6, while it also lost 
the ability to pull-down CBX7, indicating that pull-down of these endogenous proteins from 
cell lysates is highly sensitive to the positioning of the chemical tag (Supplementary Figure 
2). It is possible that biotinylation of the ligand produces a steric clash in the context of 
specific intact PRC1 complexes that can't be anticipated from CBX-only co-crystal 
structures.
While modifications to the lysine side chain did not improve the in vitro potency of our 
compounds, we sought to compare the cellular activity of compound 39 (containing Kme3) 
to compound 1 since we initially hypothesized that replacement of the Kme3 would improve 
passive membrane permeability. We first measured the intracellular concentration of 39. 
Treatment at a 30 µM extracellular dose of 1 for 24 hours results in an intracellular 
concentration of 1.4 ± 0.3 µM in PC3 cells.10 Under the same conditions, we observed an 
intracellular concentration of 0.61 ± 0.2 µM of compound 39. It was surprising that 
incorporation of trimethyl-lysine resulted in only an approximately 2-fold decrease in the 
permeability of the compound, and we were intrigued to investigate whether 39 was 
functionally available for chromodomain binding in cells since it is known that highly 
charged compounds may accumulate in endosomes and lysosomes.24, 25
Previously, we have shown that 1 inhibits PC3 cell proliferation through antagonism of 
polycomb CBX chromodomains. In order to assess the effect of Kme3 substitution on 
functional activity, we compared the anti-proliferative effects of 1 and 39 to our negative 
control analog of 1, compound 49 (UNC4219). Compound 49 contains a single backbone 
methylation which ablates its ability to interact with chromodomains.10 Despite having 
nearly identical in vitro potencies for CBX chromodomains as 1 and only a 2-fold reduction 
in permeability, compound 39 had no effect on PC3 cell proliferation, analogous to the 
negative control (Figure 4), supporting our hypothesis that Kme3 replacement is required for 
cellular activity. We suspect that the lack of biological activity observed upon treatment with 
compound 39 may be a result of endosomal and lysosomal trapping of the molecule.24, 25
As discussed previously, our proposed binding model involves an induced-fit mode of 
recognition in which the N-terminus of these ligands makes the first specific contact with 
CBX7 and that initial hydrophobic interaction nucleates a series of backbone hydrogen 
bonds, allowing CBX7 to close and the aromatic cage to form to generate the stably bound 
state. While we were able to apply this model to develop more potent chromodomain 
antagonists, largely through modification of the N-terminal aromatic capping group, we 
were motivated to further interrogate the validity of the model. We therefore turned to 
surface-plasmon resonance (SPR) studies with CBX7 and a subset of our compounds that 
differ at the N-terminus in order to determine if the binding kinetics could provide any 
evidence to further support this induced-fit hypothesis.
When first comparing the SPR data for compound 18 (Figure 5 and Supplementary Figure 
3), which contains the larger benzoyl glycine N-terminus, to the ortho-Me phenyl derivative 
(28), both of which have similar IC50's for CBX7, we observed that the kon for compound 28 
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was slightly faster but that the koff increased in a proportional manner, resulting in 
comparable affinities. When the methyl group of compound 28 is shifted to the meta-
position (compound 29), the higher potency observed for this compound is largely driven by 
a significant increase in kon. Moving the methyl substituent to the para-position (compound 
30) did not substantially change the kon relative to compound 29 but did slightly improve 
koff, resulting in the 3-fold improvement in CBX7 potency for 30 over 29 observed in 
AlphaScreen®. Inclusion of a para-t-butyl moiety in 1 further improves both kon and koff, 
resulting in one of our most potent CBX7 inhibitors to date.
We were intrigued by the fact that the majority of the potency improvements resulting from 
modification of the N-terminus were driven primarily by enhanced association rates instead 
of decreased dissociation rates.26 Based on molecular dynamics simulations, we believe that 
N-terminal portion of these molecules forms the first stable interaction with CBX7, which is 
consistent with modifications at this position primarily affecting the association kinetics. 
More specifically, the improvement in association kinetics may result from a reduction in the 
conformational flexibility at the N-terminus, thereby increasing the likelihood of a 
productive binding collision between CBX7 and the antagonist. SPR results with CBX7 and 
compound 36, which is approximately 100-fold less potent than 1 for CBX7, demonstrate 
that insertion of a flexible methylene linker primarily reduced kon while koff was minimally 
affected. Finally, analysis of the kon and koff rates of these select compounds with respect to 
their Kd's (Figure 5c) revealed that the binding is better correlated with kon as opposed to 
koff, providing even stronger support for this hypothesis.
Conclusions
The studies presented herein build on previous work investigating structure-activity 
relationships of peptide-based antagonists for Pc CBX chromodomains.8-10 In particular, we 
performed the first systematic effort to replace Kme3 with non-natural lysine derivatives and 
found that tertiary amine Kme3 mimetics are not only tolerated, but are able to maintain 
similar affinities for chromodomains. Replacement of Kme3 was also found to be critical for 
cellular activity of these ligands.
A thorough examination of the N-terminus of our inhibitors has also begun to establish the 
requirements for optimizing potency and selectivity for the Pc, HP1 and CDY families of 
chromodomains. While CDYL2 appears to be much more tolerant of various modifications 
at this position in our studies, CBX chromodomains show a strong preference for alkyl 
substituents located at the para-position of an N-terminal benzoyl cap. Pc chromodomains 
tend to prefer larger alkyl substituents at this position while the CBX5 chromodomain 
interacts more favorably with smaller substituents or an unmodified benzoyl group at this 
position. Further studies will help to elaborate on the requirements for CBX selectivity at 
this position, and we are currently pursuing alternative approaches toward the discovery and 
optimization of selective chromodomain ligands via an affinity-based, one-bead one-
compound, target class screening strategy.27
Our SPR studies have provided strong support for the hypothesized induced-fit binding 
mechanism for these antagonists with CBX7. These studies have revealed what is, to our 
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knowledge, the first example of a protein-ligand system with an exploitable SAR to control 
potency via optimization of association kinetics. Further, these studies have demonstrated 
that the residence time of compound 1 on CBX7 is quite short (∼100 seconds). There are an 
increasing number of examples where the cellular efficacy of drugs and probes are better 
correlated with the residence time than the binding constant.26 Therefore, we are currently 
working to apply our knowledge of the binding pathway to increase the residence time of 
these ligands in order to assess whether this will improve their cellular and in vivo efficacy.
Experimental Section
Expression constructs
The chromodomains of CBX4 (residues 8-65 of NP_003646), CBX5 (residues 18-75 of 
NP_036429) and CBX8 (residues 8-61 of NP_065700) were expressed with N-terminal His-
tags in pET28 expression vectors. The chromodomain of CBX7 (residues 8-62 of 
NP_783640) and CDYL2 (residues 1-75 of NP_689555) were expressed with a C-terminal 
His-tag in a pET30 expression vector.
AlphaScreen® procedure and conditions
The AlphaScreen® assay was generally performed as previously described.19 In brief, 
compound plates (1 µL at 10 mM highest concentration; 3-fold, 10-point dilutions in 
DMSO) were diluted in 1× assay buffer (20 mM TRIS pH 7.5, 75 mM NaCl, 2 mM DTT 
and 0.05% Tween-20) to 1 mM using a Multimek robotic pipettor (Nanoscreen) and 1 µL 
was spotted into the wells of 384-well low-volume Proxiplates (PerkinElmer). To these 
plates 9 µL of protein-peptide mix in 1× assay buffer was added by Multidrop (Thermo) to 
bring the final compound concentration to 100 µM and incubated for 30 min at room 
temperature. Next, 2 µL of a 1:1 mixture of streptavidin-conjugate donor and nickel-chelate 
or α-GST acceptor beads (45 µg/mL in 1× assay buffer) were added and the plates were 
allowed to incubate for an additional 30 min in the dark at room temperature. After 
incubation, the plates were read on an EnVision multi-label reader equipped with an HTS 
AlphaScreen laser (Perkin Elmer). Dose-response curves were fit using a 4-parameter or 3-
parameter fixed top binding equation.
Compound permeability studies
PC3 cells were cultured until reaching ∼80% confluency in a T75 cell culture flask. The 
media was exchanged with 10 mL fresh media (0.3% DMSO) containing 30 µM compound. 
Cells were incubated with compound for 24 hours. After 24 hours, cells were washed with 
PBS, trypsinized, and wash again with PBS. The resulting cell pellets (3) were flash frozen 
with liquid nitrogen and submitted to Drumetix Laboratories (Greensboro, NC) for analysis 
by LC-MS/MS.
Pull-down studies
Cells were cultured on a T175 tissue culture flask until reaching ∼80-90% confluency. 
Following trypsinization, the pellet was washed twice with PBS and lysed with 500 µL of 
lysis buffer. When applicable, vehicle control or 100 µM of compound 1 was added to an 
aliquot of 1000 µg of total protein and diluted to 500 µL with 20 mM Tris (pH 8)/150 mM 
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NaCl/0.1% Tween-20 (TBST). Pull-down reagents were bound to Streptavidin M-280 
Dynabeads® by rotating 30 µL of beads with a 20-fold excess of pull-down reagent for 30 
minutes at room temperature in. Unbound pull-down reagent was then removed and the 
beads were washed 3× with 200 µL of TBST. The lysate was then transferred to an 
Eppendorf tube containing 30 µL of Streptavidin M-280 Dynabeads® that had been pre-
bound to biotin-46. The mixture was rotated for 2 hr at 4°C. The depleted lysate was 
removed and the beads were washed 3× with 300-500 µL of TBST. The beads were re-
suspended with 30 µL of 1× Laemmli sample buffer and heated at 95°C for 3 minutes. 
Fifteen microliters of the sample was then loaded into a gel and analyzed via western 
blotting using the appropriate primary antibody and detected using a LI-COR Odyssey® 
instrument and the appropriate fluorescent secondary antibodies (diluted 1:10, 000 in 
PBST). One percent of input was used for western blotting of all proteins.
Cell Proliferation Experiments
PC3 cells were seeded at 400 cells/well into 96-well plates. Cells were allowed to adhere 
overnight. The media (DMEM supplemented with 10 % FBS) was then exchanged with 
fresh media containing DMSO, or 30 µM of the indicated compound. On day three, the cells 
were fixed with ice-cold methanol for 30 sec. and rehydrated with PBS. Nuclei of the cells 
were stained with DAPI (0.05 µg/ml) and numerated using High Content Microscopy (Array 
Scan™ High Content Analysis, Thermo Fisher #NX10002L).
Surface Plasmon Resonance Experiments
SPR experiments were performed on a ProteOn™ XPR36 Interaction Array System. C-
terminally His-tagged CBX7 was immobilized using a ProteOn™ HTE sensor chip. 
Compounds were flowed at a rate of 50-100 µL/minute with a contact time of 150 seconds. 
Dissociation steps were run for 300 seconds at a flow rate of 100 µL/minute. Double 
referencing subtraction was done with buffer and protein blank channels to account for 
nonspecific binding to the sensor chip. Sample Sensorgrams are shown in Supplementary 
Figure 3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
CBX2 chromobox homolog protein 2
CBX4 chromobox homolog protein 4
CBX5 chromobox homolog protein 5
CBX6 chromobox homolog protein 6
CBX7 chromobox homolog protein 7
CBX8 chromobox homolog protein 8
HP1 Heterochromatin protein 1
Kme methyl-lysine
PRC1 Polycomb repressive complex 1
SPR surface plasmon resonance
Pc Polycomb
CDYL2 chromodomain protein, Y-like 2
DMSO dimethyl sulfoxide
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Figure 1. Compound 1 and its chromodomain targets
(Top) Structure of 1, a cell-active peptidic antagonist of CBX and CDY chromodomains. 
(Bottom) Domain maps of human CBX and CDY chromodomains as annotated in Uniprot. 
The Kd of compound 1 as determined by ITC for each of the chromodomains is listed.
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Figure 2. (a) X-ray crystal structure of compound 1 bound to CBX7 (PDB 5EPJ)
Compound 1 (yellow) binds in an extended groove along the surface of the chromodomain 
of CBX7 (light blue). The interaction involves multiple hydrogen bonds (black dashes) 
between CBX7 and the backbone amides of 1. The high affinity of this interaction is driven 
by hydrophobic contacts between the t-butyl group of 1 and the side chains of Leu48, Asp49 
and Arg51. The different regions of compound 1 explored in this study are indicated. (b) 
Structure of compound 2. The biotin affinity tag was added to the C-terminus of 1 which is 
solvent exposed, and 2 retains high affinity for CBX7.
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Figure 3. Compound 1 bound to CBX7 (PDB 5EPJ)
(a) Interaction of the CBX7 aromatic cage with diethyl-lysine. (b) Binding pocket of CBX7 
occupied by the Ala side chain of 1. (c) Position of Phe of 1 when bound to CBX7.
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Figure 4. Effect of compounds 1, 39, and 49 on PC3 cell proliferation
Cells were treated for 72 hours with the indicated compounds (30 µM) or DMSO, fixed and 
DAPI stained. Cell counts were numerated using high content microscopy and normalized to 
DMSO control (n ≥ 4).
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Figure 5. 
(a) Comparison of compound-CBX7 associates rates. (b) Comparison of compound-CBX7 
dissociation rates. Negative log values of the dissociation rates (1/s) are shown. Data are 
reported as the mean ± the standard error of the mean (n ≥ 5). (c) CBX7 binding affinities of 
compounds with N-terminal variations are better correlated with the association rates as 
compared to the dissociation rates. The log transformations of kon (1/M/s), koff (1/s) and Kd 
(nM) are plotted.
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